AMDL Diagnostics, Inc. Enters Into Exclusive Distribution Agreement With Grifols USA, LLC to Advance Commercialization of DR-70 Onko-Sure(TM) Cancer Test

AMDL Diagnostics, Inc. Enters Into Exclusive Distribution Agreement With
Grifols USA, LLC to Advance Commercialization of DR-70 Onko-Sure(TM) Cancer
Test
Partnership to expand marketing & sales in the USA

TUSTIN, Calif., Oct. 8 /PRNewswire-FirstCall/ -- Radient Pharmaceuticals
Corporation (NYSE Amex: RPC), a US-based pharmaceutical company through its
wholly-owned subsidiary AMDL Diagnostics, Inc. (ADI) announced today it has
entered into an exclusive 5-year marketing and distribution agreement with
Grifols USA, LLC. Under the terms of the agreement, Grifols USA, LLC will
market and sell ADI's DR-70 Onko-Sure cancer test for the monitoring of
colorectal cancer (CRC) to hospitals, clinical labs, clinics, and other
healthcare organizations throughout the US.

Grifols is a publicly-traded, multinational healthcare products manufacturer
and distributor. The company has business operations in more than 90
countries worldwide focused on the research and development, manufacturing,
distribution, marketing, sales, and customer support for a diverse range of
in-house and 3rd party healthcare products and services, now including ADI's
DR-70 Onko-Sure cancer test.

The agreement is the latest milestone ADI has achieved in support of the
company's aggressive commercialization strategy for Onko-Sure. According to
the agreed upon terms, Grifols USA, LLC has the rights to market and
distribute ADI's Onko-Sure cancer test specifically for the monitoring of
colorectal cancer in the US. This includes developing and implementing a
marketing strategy to drive product awareness; educate clinical laboratories
and physicians; and generate product sales.

According to Patricia Silver, General Manager, US Diagnostic Division at
Grifols USA, LLC, "We are intensely dedicated to providing hospitals, labs and
clinics with highly innovative and in-demand products and services which
improve the level and quality of patient health care around the world, and we
are very pleased to support the commercialization of ADI's Onko-Sure cancer
test in the US. ADI has developed a new option to assist physicians and their
patients in monitoring the recurrence of cancer and we are excited to bring it
to the marketplace."

"We are extremely pleased to announce a top-tier distribution partnership for
our Onko-Sure cancer test in the USA," commented Mr. Douglas MacLellan,
Chairman and CEO of Radient Pharmaceuticals & ADI. "We are making great
progress on our commercialization plan for Onko-Sure(TM), and with this latest
agreement, doing so with one of the most recognized, respected and experienced
companies in the healthcare sector. We are dedicated to establishing a
strong, long-lasting and highly successful relationship with the Grifols team
- one that will help make Onko-Sure(TM) the standard in cancer testing and
deliver direct value to our customers, patients, and shareholders."

With the exception of heart disease, cancer causes more deaths than any other
medical condition in the world. According to the World Health Organization
(WHO), cancer is rapidly becoming the leading cause of death worldwide and is
expected to overtake heart disease by 2010. Colorectal cancer is the third
most common cancer worldwide and the second leading cause of cancer deaths
irrespective of gender in the US, and one of the most commonly diagnosed of
all cancers. Last year, there were approximately 151,000 new cases diagnosed
in the US, roughly 51,000 deaths due to the disease*, and almost half of all
patients thought to be "cured" are expected to develop a recurrence of CRC
within 5 years - usually due to undetected metastases.** Frequent surveillance
of diagnosed patients is recommended.

In the USA Onko-Sure has been cleared for the monitoring of colorectal cancer
by the US FDA (July 2008). ADI continues to expand its commercialization of
Onko-Sure(TM) in select international markets. For additional information on
ADI and its portfolio of products visit the Company's corporate website at
www.Radient-Pharma.com. For Investor Relations information contact Kristine
Szarkowitz at kszarkowitz@Radient-Pharma.com or 1.206.310.5323.

*National Cancer Institute: Cancer Facts and Figures 2009.
**Bull World Health Organ: Shike M, Winawer SJ, Greenwald PH, et al.

About Radient Pharma:
Headquartered in Tustin, California, Radient Pharmaceuticals Corporation is an
integrated pharmaceutical company devoted to the research, development,
manufacturing, and marketing of diagnostic and premium skin care products.

About Grifols S.A.
Grifols S.A. is a Spain-based company engaged in the healthcare sector and is
listed on Ibex-35 stock market. Grifols is involved in the research,
development, manufacturing and marketing of plasma derivates, IV therapy
solutions, enteral and parenteral nutrition, diagnostic systems, pharmacy
automation, and medical materials and devices. Founded in 1940, Grifols
currently operates in 90 countries with more than 6.000 employees, 26
subsidiaries with combined gross revenues over Euro 800 million.

Forward Looking Statements:
Safe Harbor Statement under the Private Securities Litigation Reform Act of
1995: The statements contained in this document include certain predictions
and projections that may be considered forward-looking statements under
securities law. These statements involve a number of important risks and
uncertainties that could cause actual results to differ materially including,
but not limited to, the performance of joint venture partners, as well as
other economic, competitive and technological factors involving the Company's
operations, markets, services, products, and prices. With respect to Radient
Pharmaceuticals Corporation, except for the historical information contained
herein, the matters discussed in this document are forward-looking statements
involving risks and uncertainties that could cause actual results to differ
materially from those in such forward-looking statements.

Radient Pharmaceuticals Corporation Contact:
Kristine Szarkowitz
Director-Investor Relations
kszarkowitz@radient-pharma.com
(Tel:) 206.310.5323

SOURCE Radient Pharmaceuticals Corporation

Kristine Szarkowitz, Director-Investor Relations of Radient Pharmaceuticals
Corporation, +1-206-310-5323, kszarkowitz@radient-pharma.com